In a latest development, Noxopharm (ASX: NOX) notified that two sets of clinical data relating to the development of Veyonda® (NOX66) as a treatment of end-stage cancer has been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting.
The two sets of data presented at the global oncology conference, include:
- Details of the DARRT-1 Phase 1b clinical study
- Interim data from the Phase 1b/2a LuPIN clinical trial
The presentation of data allowed Noxopharm to reference the Veyonda® clinical data against that of other technologies.
NOX is trading 2.3% higher on the ASX, at $0.220 (as at 11:50 AM AEST).